Comparison 14. Efficacy at three years: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. etanercept.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 ACR20	1	454	Risk Ratio (M‐H, Fixed, 95% CI)	1.18 [1.07, 1.31]
1.1 Etanercept 25 mg SC twice weekly	1	454	Risk Ratio (M‐H, Fixed, 95% CI)	1.18 [1.07, 1.31]
2 ACR50	1	454	Risk Ratio (M‐H, Fixed, 95% CI)	1.44 [1.22, 1.71]
2.1 Etanercept 25 mg SC twice weekly	1	454	Risk Ratio (M‐H, Fixed, 95% CI)	1.44 [1.22, 1.71]
3 ACR70	1	454	Risk Ratio (M‐H, Fixed, 95% CI)	2.04 [1.56, 2.66]
3.1 Etanercept 25 mg SC twice weekly	1	454	Risk Ratio (M‐H, Fixed, 95% CI)	2.04 [1.56, 2.66]
4 Remission (DAS < 1.6)	1	454	Risk Ratio (M‐H, Fixed, 95% CI)	1.89 [1.41, 2.54]
4.1 Etanercept 25 mg SC twice weekly	1	454	Risk Ratio (M‐H, Fixed, 95% CI)	1.89 [1.41, 2.54]
5 Remission (DAS < 2.6)	1	454	Risk Ratio (M‐H, Fixed, 95% CI)	1.95 [1.44, 2.64]
5.1 Etanercept 25 mg SC twice weekly	1	454	Risk Ratio (M‐H, Fixed, 95% CI)	1.95 [1.44, 2.64]
6 Change in Total Sharp Score (TSS) (from baseline)	1	428	Mean Difference (IV, Fixed, 95% CI)	‐1.75 [‐3.27, ‐0.23]
6.1 Etanercept 25 mg SC twice weekly	1	428	Mean Difference (IV, Fixed, 95% CI)	‐1.75 [‐3.27, ‐0.23]
7 Change in Erosion Score (from baseline)	1	428	Mean Difference (IV, Fixed, 95% CI)	‐1.06 [‐1.98, ‐0.14]
7.1 Etanercept 25 mg SC twice weekly	1	428	Mean Difference (IV, Fixed, 95% CI)	‐1.06 [‐1.98, ‐0.14]
8 Change in Joint Space Narrowing Score (from baseline)	1	428	Mean Difference (IV, Fixed, 95% CI)	‐0.69 [‐1.65, 0.27]
8.1 Etanercept 25 mg SC twice weekly	1	428	Mean Difference (IV, Fixed, 95% CI)	‐0.69 [‐1.65, 0.27]
9 No progression of joint damage (TSS ≤ 0.5)	1	428	Risk Difference (M‐H, Fixed, 95% CI)	0.15 [0.06, 0.24]
9.1 Etanercept 25 mg SC twice weekly	1	428	Risk Difference (M‐H, Fixed, 95% CI)	0.15 [0.06, 0.24]